Jana Partners Raises Stake in Alkami to Over 10% and Intensifies Sale Push
The activist investor is pushing for leadership changes and a broad sale process.
Already have an account? Sign in.
The activist investor is pushing for leadership changes and a broad sale process.
Abivax advances toward Q4 2026 NDA filing with encouraging remission and safety results.
Phase 2 trials in early Parkinson’s to start Q3 2026 in U.S. & Europe after strong Phase 1 biomarker and safety data.
AeroVironment reported record Q4 FY2026 revenue of $641.6M (+133% YoY) and non-GAAP EPS of $1.84, beating expectations.